Original Research
Dec 29
Alicja Zientara, Roman Gottardi, et al.
This study evaluated the feasibility of transcatheter valve-in-root procedures in patients who had previously undergone valve-sparing root repair or Bio-Bentall procedures. Key findings include anatomical considerations that may impact the feasibility of future valve-in-root implantation.
letter to the editor
Dec 30
Nikolaos Ktenopoulos, Konstantinos Toutouzas, et al.
The study reported 1-year outcomes of tricuspid transcatheter edge-to-edge repair using the PASCAL system, showing a significant reduction in tricuspid regurgitation severity and improvements in functional status and quality of life.
free
letter to the editor
Dec 30
Stephan Baldus, Philipp Lurz, et al.
The study discusses the length of hospital stay for patients undergoing Transcatheter Tricuspid Valve Edge-to-Edge Repair (T-TEER) procedures, with a median of 4.0 days reported in the TriCLASP study.
free
Ahead of print
Dec 23
Dimytri A. Siqueira, Fausto Feres, et al.
The SURVIV trial is a randomized controlled trial comparing transcatheter mitral valve-in-valve (mViV) procedure with surgical redo-mitral valve replacement (rMVR) for patients with mitral bioprosthetic valve dysfunction, with the primary endpoint being all-cause mortality or disabling stroke at 12 months.
free
Research Correspondence
Dec 23
Lars Jakobsen, Lisette O. Jensen, et al.
The study compared the performance of the dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS) to the sirolimus-eluting stent (SES) in patients undergoing PCI. The DTS had higher early revascularization rates, despite similar long-term target lesion failure rates.
Original Research
Dec 22
Hector A. Alvarez-Covarrubias, Michael Joner, et al.
This retrospective study found that greater annular calcium volume was associated with underexpansion of the ACURATE transcatheter heart valve, while post-dilatation reduced the risk of underexpansion.
Research Correspondence
Dec 19
Victor J.M. Zeijen, Joost Daemen, et al.
Endovascular ultrasound renal denervation (uRDN) significantly reduced daytime ambulatory systolic blood pressure by 5.9 mmHg compared to sham at 2 months in patients with resistant hypertension, with the effect maintained after adjusting for changes in antihypertensive medications.
open access
Flashlight
Dec 1
Leonardo Portolan, Giovanni Luigi De Maria, et al.
This case report describes the successful implantation of a double coronary sinus Reducer device in a patient with refractory angina, complicated by proximal migration of the initial Reducer and subsequent coronary sinus thrombosis detected by cardiac CT.
Research Correspondence
Dec 18
Ghilas Rahoual, Michel Zeitouni, etc.
This study used a standardized approach combining hyperaemic absolute microvascular resistance and microvascular resistance reserve to differentiate four distinct phenotypes of coronary microvascular dysfunction.
Original Research
Dec 17
Roberto Galea, Lorenz Räber, et al.
This study compared the Watchman FLX and Watchman 2.5 left atrial appendage closure devices, finding significantly lower rates of device-related thrombus and peridevice leak with the Watchman FLX.
State-of-the-Art
Dec 16
Josep Rodés-Cabau, William T. Abraham, et al.
This content covers a range of cardiology interventions, including coronary, valvular, heart failure, peripheral, hypertension, and stroke treatments, as well as the use of advanced technologies like bioresorbable scaffolds and TAVI.
free
new issue
Dec 15
State-of-the-Art on TEER in MR; Watchman FLX vs 2.5; predictors of underexpansion with ACURATE neo; valve-in-root TAVI; CMD endotypes using invasive exercise testing; SORT OUT X: 5-year results; antihypertensive drugs in RADIANCE-HTN TRIO
Original Research
Dec 10
Antonio Landi, Marco Valgimigli, et al.
In high bleeding risk patients undergoing PCI, abbreviated antiplatelet therapy was associated with similar ischemic outcomes and reduced bleeding compared to standard therapy, regardless of chronic kidney disease status.
Editorial
Dec 12
Guillaume Marquis-Gravel, Renato D. Lopes
The content discusses the potential benefits of a shorter duration (1-3 months) of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
free
